The SWI/SNF Complex: A Frequently Mutated Chromatin Remodeling Complex in Cancer
- PMID: 38113003
- DOI: 10.1007/978-3-031-45654-1_7
The SWI/SNF Complex: A Frequently Mutated Chromatin Remodeling Complex in Cancer
Abstract
The switch/sucrose non-fermenting (SWI/SNF) chromatin remodeling complex is a global regulator of gene expression known to maintain nucleosome-depleted regions at active enhancers and promoters. The mammalian SWI/SNF protein subunits are encoded by 29 genes and 11-15 subunits including an ATPase domain of either SMARCA4 (BRG1) or SMARCA2 (BRM) are assembled into a complex. Based on the distinct subunits, SWI/SNF are grouped into 3 major types (subfamilies): the canonical BRG1/BRM-associated factor (BAF/cBAF), polybromo-associated BAF (PBAF), and non-canonical BAF (GBAF/ncBAF). Pan-cancer genome sequencing studies have shown that nearly 25% of all cancers bear mutations in subunits of the SWI/SNF complex, many of which are loss of function (LOF) mutations, suggesting a tumor suppressor role. Inactivation of SWI/SNF complex subunits causes widespread epigenetic dysfunction, including increased dependence on antagonistic components such as polycomb repressor complexes (PRC1/2) and altered enhancer regulation, likely promoting an oncogenic state leading to cancer. Despite the prevalence of mutations, most SWI/SNF-mutant cancers lack targeted therapeutic strategies. Defining the dependencies created by LOF mutations in SWI/SNF subunits will identify better targets for these cancers.
© 2023. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Similar articles
-
Glioma tumor suppressor candidate region gene 1 (GLTSCR1) and its paralog GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes.J Biol Chem. 2018 Mar 16;293(11):3892-3903. doi: 10.1074/jbc.RA117.001065. Epub 2018 Jan 26. J Biol Chem. 2018. PMID: 29374058 Free PMC article.
-
BAFfling pathologies: Alterations of BAF complexes in cancer.Cancer Lett. 2018 Apr 10;419:266-279. doi: 10.1016/j.canlet.2018.01.046. Epub 2018 Jan 31. Cancer Lett. 2018. PMID: 29374542 Review.
-
Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.Mol Cell Biol. 2014 Mar;34(6):1136-44. doi: 10.1128/MCB.01372-13. Epub 2014 Jan 13. Mol Cell Biol. 2014. PMID: 24421395 Free PMC article.
-
Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.BMC Cancer. 2020 Jan 6;20(1):12. doi: 10.1186/s12885-019-6425-3. BMC Cancer. 2020. PMID: 31906887 Free PMC article.
-
Preclinical evidence in the assembly of mammalian SWI/SNF complexes: Epigenetic insights and clinical perspectives in human lung disease therapy.Mol Ther. 2024 Aug 7;32(8):2470-2488. doi: 10.1016/j.ymthe.2024.06.026. Epub 2024 Jun 22. Mol Ther. 2024. PMID: 38910326 Free PMC article. Review.
Cited by
-
Targeting SWI/SNF Complexes in Cancer: Pharmacological Approaches and Implications.Epigenomes. 2024 Feb 4;8(1):7. doi: 10.3390/epigenomes8010007. Epigenomes. 2024. PMID: 38390898 Free PMC article. Review.
-
Epigenetic Dysregulation in Cancer: Implications for Gene Expression and DNA Repair-Associated Pathways.Int J Mol Sci. 2025 Jul 7;26(13):6531. doi: 10.3390/ijms26136531. Int J Mol Sci. 2025. PMID: 40650308 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous